Theranostics in Neuroblastoma

Margarida Simao Rafael; Sarah Cohen-Gogo; Meredith S Irwin; Reza Vali; Amer Shammas; Daniel A Morgenstern

doi:10.1016/j.cpet.2021.03.006

Theranostics in Neuroblastoma

PET Clin. 2021 Jul;16(3):419-427. doi: 10.1016/j.cpet.2021.03.006.

Authors

Margarida Simao Rafael¹, Sarah Cohen-Gogo¹, Meredith S Irwin¹, Reza Vali², Amer Shammas³, Daniel A Morgenstern¹

Affiliations

¹ Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto, ON M5G 1X8, Canada.
² Division of Nuclear Medicine, Department of Diagnostic Imaging, The Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto, ON M5G 1X8, Canada. Electronic address: reza.vali@sickkids.ca.
³ Division of Nuclear Medicine, Department of Diagnostic Imaging, The Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto, ON M5G 1X8, Canada.

PMID: 34053585
DOI: 10.1016/j.cpet.2021.03.006

Abstract

Theranostics combines diagnosis and targeted therapy, achieved by the use of the same or similar molecules labeled with different radiopharmaceuticals or identical with different dosages. One of the best examples is the use of metaiodobenzylguanidine (MIBG). In the management of neuroblastoma-the most common extracranial solid tumor in children. MIBG has utility not only for diagnosis, risk-stratification, and response monitoring but also for cancer therapy, particularly in the setting of relapsed/refractory disease. Improved techniques and new emerging radiopharmaceuticals likely will strengthen the role of nuclear medicine in the management of neuroblastoma.

Keywords: MIBG; MIBG therapy; Neuroblastoma; PET-[(18)F]FDG; Theranostics.

Publication types

Review

MeSH terms

3-Iodobenzylguanidine
Child
Humans
Neuroblastoma* / diagnostic imaging
Precision Medicine*
Radionuclide Imaging
Radiopharmaceuticals

Substances

Radiopharmaceuticals
3-Iodobenzylguanidine